Fernando Bessone

7.1k total citations · 1 hit paper
80 papers, 2.3k citations indexed

About

Fernando Bessone is a scholar working on Hepatology, Epidemiology and Pharmacology. According to data from OpenAlex, Fernando Bessone has authored 80 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hepatology, 45 papers in Epidemiology and 37 papers in Pharmacology. Recurrent topics in Fernando Bessone's work include Liver Disease Diagnosis and Treatment (39 papers), Drug-Induced Hepatotoxicity and Protection (37 papers) and Hepatitis C virus research (28 papers). Fernando Bessone is often cited by papers focused on Liver Disease Diagnosis and Treatment (39 papers), Drug-Induced Hepatotoxicity and Protection (37 papers) and Hepatitis C virus research (28 papers). Fernando Bessone collaborates with scholars based in Argentina, Uruguay and Spain. Fernando Bessone's co-authors include Marcelo G. Roma, María Valeria Razori, Nelia Hernández, Raúl J. Andrade, M. Isabel Lucena, Melisa Dirchwolf, Inmaculada Medina‐Cáliz, Mercedes Robles‐Díaz, Camilla Stephens and Marco Arrese and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Fernando Bessone

78 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular pathways of nonalcoholic fatty liver disease development and progression

2018 458 citations Fernando Bessone, Marcelo G. Roma et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fernando Bessone Argentina	23	1.4k	1.0k	662	267	225	80	2.3k
Yves Horsmans Belgium	29	852 0.6×	721 0.7×	439 0.7×	401 1.5×	396 1.8×	93	2.3k
Margaret C. Shuhart United States	21	759 0.6×	857 0.8×	291 0.4×	213 0.8×	99 0.4×	32	1.6k
Lars P. Bechmann Germany	28	1.9k 1.4×	1.1k 1.0×	373 0.6×	721 2.7×	270 1.2×	79	3.2k
Yasuhiro Takikawa Japan	25	1.2k 0.9×	1.3k 1.2×	299 0.5×	410 1.5×	224 1.0×	121	2.4k
Filomena Morisco Italy	33	2.0k 1.5×	1.6k 1.5×	255 0.4×	558 2.1×	227 1.0×	166	3.8k
Behnam Saberi United States	18	592 0.4×	648 0.6×	535 0.8×	439 1.6×	235 1.0×	76	1.8k
Cyriac Abby Philips India	22	997 0.7×	727 0.7×	285 0.4×	463 1.7×	103 0.5×	135	1.8k
Mercedes Robles‐Díaz Spain	20	561 0.4×	416 0.4×	1.2k 1.8×	215 0.8×	409 1.8×	63	1.8k
Shigeru Ohmori Japan	27	410 0.3×	612 0.6×	648 1.0×	598 2.2×	428 1.9×	132	2.3k
Mario Masarone Italy	29	1.9k 1.4×	939 0.9×	140 0.2×	442 1.7×	159 0.7×	93	2.9k

Countries citing papers authored by Fernando Bessone

Since Specialization

Citations

This map shows the geographic impact of Fernando Bessone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Bessone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Bessone more than expected).

Fields of papers citing papers by Fernando Bessone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Bessone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Bessone. The network helps show where Fernando Bessone may publish in the future.

Co-authorship network of co-authors of Fernando Bessone

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Bessone. A scholar is included among the top collaborators of Fernando Bessone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Bessone. Fernando Bessone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bessone, Fernando, et al.. (2025). Ursodeoxycholic Acid for the Management of Drug-induced Liver Injury: Role of Hepatoprotective and Anti-cholestatic Mechanisms. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 3 indexed citations

Schinoni, María Isabel, Fernando Bessone, M. Isabel Lucena, et al.. (2025). Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation. Journal of Clinical and Experimental Hepatology. 15(3). 102506–102506.

Björnsson, Einar S., et al.. (2024). Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors. Liver International. 45(4). e16163–e16163. 3 indexed citations

García‐Cortés, Miren, Aida Ortega‐Alonso, Inmaculada Medina‐Cáliz, et al.. (2023). Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver International. 43(8). 1749–1760. 13 indexed citations

Acosta, Julián, et al.. (2021). Zoonotic transmission of hepatitis E virus in a pig farmer from Argentina: A case report. Zoonoses and Public Health. 69(3). 235–241. 4 indexed citations

Bessone, Fernando, Nelia Hernández, Martín Tagle, et al.. (2021). Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Annals of Hepatology. 24. 100321–100321. 34 indexed citations

Arab, Juan Pablo, Juan Pablo Roblero, José Altamirano, et al.. (2019). Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Annals of Hepatology. 18(3). 518–535. 68 indexed citations

Zoubek, Miguel Eugenio, A. González-Jiménez, Inmaculada Medina‐Cáliz, et al.. (2017). High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. Clinical Gastroenterology and Hepatology. 16(2). 292–294. 16 indexed citations

Ridruejo, Ezequiel, Fernando Bessone, Jorge Daruich, et al.. (2016). Hepatitis C virus infection in Argentina: Burden of chronic disease. World Journal of Hepatology. 8(15). 649–649. 5 indexed citations

10.

Bessone, Fernando, et al.. (2016). The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. International Journal of Molecular Sciences. 17(3). 313–313. 53 indexed citations

11.

Andrade, Raúl J., et al.. (2015). [Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela].. PubMed. 56(1). 3–12. 5 indexed citations

12.

Robles‐Díaz, Mercedes, M. Isabel Lucena, Neil Kaplowitz, et al.. (2014). Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. Gastroenterology. 147(1). 109–118.e5. 223 indexed citations

13.

Bronowicki, Jean–Pierre, Vlad Ratziu, Adrián Gadano, et al.. (2014). Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology. 61(6). 1220–1227. 21 indexed citations

14.

Bronowicki, J.‐P., Vlad Ratziu, Adrián Gadano, et al.. (2013). 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016). Journal of Hepatology. 58. S571–S572. 10 indexed citations

15.

Sulkowski, Mark, Tarik Asselah, Jacob Lalezari, et al.. (2013). Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. Hepatology. 57(6). 2143–2154. 86 indexed citations

16.

Paraná, Raymundo, Mário Guimarães Pessôa, Javier C. Waksman, et al.. (2011). Reunião com expertos em hepatotoxicidade da Sociedade Brasileira de Hepatologia: analgésicos, antitérmicos, insumos vegetais, fitoterápicos, homeopáticos e AINEs. 30. 5–47. 1 indexed citations

17.

Lucena, M. Isabel, Henry Cohen, Nelia Hernández, et al.. (2011). Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterología y Hepatología. 34(5). 361–368. 8 indexed citations

18.

Schiff, Eugene R., Samuel S. Lee, You‐Chen Chao, et al.. (2010). Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology. 9(3). 274–276.e1. 137 indexed citations

19.

Bessone, Fernando. (2009). HIV/HCV COINFECTION. 79(1). 3 indexed citations

20.

Bessone, Fernando. (2008). Hepatitis crónica B (HCB): ¿cuál es la mejor opción de tratamiento?. SHILAP Revista de lepidopterología. 38(2). 152–160. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact